Can a blister beetle extract banish common warts? phase 3 trial investigates

NCT ID NCT07637734

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests YCANTH, a topical solution containing cantharidin (a substance from blister beetles), against a placebo for treating common warts. About 300 people aged 2 and older with at least one wart on their body (excluding certain areas) will receive either the active treatment or a vehicle control. The main goal is to see if YCANTH can completely clear all treatable warts by day 84, with a secondary focus on sustained clearance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
YCANTH (cantharidin topical solution)
What this could lead to
If successful, this could provide a proven, safe topical treatment for common warts, potentially clearing them without invasive procedures.
What could go wrong
This is a Phase 3 trial, but results may not apply to all wart types or locations. Some people may not respond, and side effects like blistering or pain are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMON WARTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • DelRicht Research

    Overland Park, Kansas, 66209, United States

  • DelRicht Research

    Baton Rouge, Louisiana, 70809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.